logo
Warwick Resort Fiji alcohol 'poisoning' victim speaks after near-death experience

Warwick Resort Fiji alcohol 'poisoning' victim speaks after near-death experience

It was supposed to be a relaxing mother-daughter holiday in Fiji — and for the most part, it was.
Staying at the Warwick Resort, one of Fiji's most-well known and trusted establishments, Susan*, 58, and her 18-year-old daughter were on their final day of what she says was an almost perfect holiday.
They toured a local village, snorkelled and relaxed around the pool.
Then, in the afternoon, Susan's daughter bought a pina colada cocktail from the Warwick Resort pool bar where they were staying.
It's a decision that would change both of their lives.
"She came up to the room with the cocktail and said 'mum, try this, it tastes really weird,'" Susan told the ABC.
"So I had two sips of the cocktail, and said 'hmmm, you know, not sure".
Fast forward five hours and Susan was unconscious.
She spent the next three days in an induced coma in a Fijian hospital, intubated and fighting for her life.
She was then flown on an emergency medivac mission out of Fiji and spent a further week in the intensive care unit at a hospital in Australia.
"Without [the help we got] I would be dead."
In December, Fiji's Warwick Resort made global headlines after authorities revealed seven tourists, including Susan, had been taken to hospital with suspected alcohol poisoning after drinking pina coladas at the resort's pool bar.
The revelation came less than a month after the deaths of Melbourne teenagers Holly Bowles from methanol poisoning after drinking tainted alcohol at a hostel in Laos.
At the time, it was feared the seven tourists in Fiji may have also consumed methanol.
Four days after the incident, Fiji's government released the results of its tests of the drinks, declaring there was "no methanol" found.
And in March, three months after the incident — and after multiple delays — it revealed the results of blood and urine samples sent to New Zealand, declaring again there was "no methanol".
But now, more than five months on, it is still unclear what actually caused the seven tourists, including Susan, to suffer such a horrific reaction on that Saturday afternoon in December, and be taken to hospital.
No one has ever been interviewed about the incident, until now.
Susan, who spoke to the ABC on the condition she not be identified, to protect her daughter who is "traumatised" after watching the events unfold in Fiji, said she is crystal clear about what happened to her.
"The only commonality between the seven victims was that we were all in the pool and we all drunk a pina colada within an hour of each other."
She believes there has been a "cover up", in part to protect Fiji's multimillion-dollar tourism industry. And, she said, the group of seven guests involved in the incident are speaking to a lawyer to explore action against the resort, which she said had failed in its duty of care.
"We want some sort of acceptance of responsibility, probably from the Warwick, foremost, but also from the Fiji authorities who we feel have tried to shut down or underplay what happened."
After initially agreeing to an interview, the Warwick Hotel later declined the ABC's request. It also declined to answer any questions.
Susan remembers the day in question clearly up until she fell into a coma.
She remembers her daughter buying the drink, tasting it, then going snorkelling.
"By the time I got out, [my daughter] found me, and she was hysterical, she was having like an allergic-type reaction to the drink," she said.
"Her hands were shaking, she said her mouth was really tingly, and when she drunk water it tasted like sand."
They were both taken to the local clinic, then to the Lautoka Hospital, when Susan also started to get the shakes and what she described as "the same mouth feel".
"By that stage, some of the other Warwick Resort guests had started to come in [to the hospital]."
"There were eight beds in there, and pretty much all of the beds became full of Warwick guests.
"I could see in the room that other people were going to various states of seizures and other experiences.
"I was going downhill very fast. I was shaking violently and I could see the other medical staff were busy with the other patients, and I was like, 'don't forget about me', and that's all I remember. That's the last time I was conscious."
Susan, along with another one of of the guests, was intubated.
Specialists later told her that her heart went into "stress cardio myopathy" due to what was happening with her brain following the seizures, and her heart function went down to 25 per cent, with fluid build-up around her heart.
Susan has had astroke previously, and her scans showed additional damage around her frontal lobe following the incident.
Susan, a financial accounts manager, hasn't been able to work since the incident and, because of her seizures, her driver's licence has been cancelled.
Now, as she continues to recover, she's searching for answers.
She said the Fijian authorities promised to get the alcohol ingredients independently tested, which never happened.
Fiji's Tourism Minister Viliame Gavoka declined an interview, but in a statement said he "deeply regrets the unfortunate circumstances" encountered by the visitors during their stay.
He said the Fijian government has been working in close collaboration with the respective government representatives in Suva to keep them informed and provide necessary support.
He the Fijian government collaborated with the New Zealand government to ensure a "thorough and independent analysis" of the samples taken.
"We wish to reiterate that initial testings did not reveal any presence of illicit substances," he said.
Susan and her daughter are in a WhatsApp group with the fellow five Warwick Hotel guests involved, which she says has been a "great support".
She said the Warwick Hotel has never contacted them since the incident, and they will keep pressing for answers.
"Why haven't you reached out to the victims? Or offered any sort or apology?" she said.
"I don't want this to happen to any future guest. It was so traumatising."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

National review launched into IVF accreditation following second Monash embryo mix-up
National review launched into IVF accreditation following second Monash embryo mix-up

ABC News

time3 hours ago

  • ABC News

National review launched into IVF accreditation following second Monash embryo mix-up

All Australian states and territories will undertake a review into the implementation of an independent verification body for fertility providers. Victorian Health Minister Mary-Anne Thomas said health ministers met on Friday and agreed to a three-month rapid-review into the sector, which is currently accredited by the Reproductive Technology Accreditation Committee. "It simply doesn't pass the pub test that the people that provide the service are also the ones that determine who provides the service," she said. The announcement comes after two separate embryo mix-ups by Melbourne-based provider Monash IVF were revealed in a matter of months. Ms Thomas said her preference was for the immediate implementation of a regulator, however this was rejected by Queensland Health Minister Tim Nicholls. Ministerial meetings by health ministers operate on a consensus, meaning all ministers must agree to make any changes nationally. "I think it's concerning that there may well be further errors that we don't know about," she said. "And that is because the body that currently accredits fertility care providers is made up of fertility care providers. that's why I find Queensland's position so perplexing." This week, Monash IVF announced to the ASX it would conduct an internal investigation into an embryo mix-up at its Clayton laboratory in Melbourne's south-east earlier this month. That announcement, which came months after the revelation another patient of Monash IVF in Brisbane gave birth to a stranger's baby in 2023, sparked calls for greater regulation of the field. Monash IVF chief executive officer Michael Knaap also resigned earlier this week. On Friday afternoon Mr Butler said he was "really worried about public confidence" in the sector, which he said needed greater transparency and independent accreditation for fertility service providers. "We know that in the last full year there were dozens of breaches of the code of conduct but I don't know, as the federal health minister, what they were," he said. "They are not reported, they are not disclosed." He said health officials across the country would provide advice on whether Australia should move towards national regulations. "There are essentially eight systems of regulation across the country," he said. "It would take a bit of time to move to more national regulation."

Scott Power: ASX stocks fall as investors hear mixed news from Cochlear
Scott Power: ASX stocks fall as investors hear mixed news from Cochlear

News.com.au

time4 hours ago

  • News.com.au

Scott Power: ASX stocks fall as investors hear mixed news from Cochlear

ASX heath sector falls 1.1% over past five days, while broader markets flat as Middle East tensions flare Cochlear downgrades full-year profit expectations but launches a world first Monash IVF head Michael Knaap resigns after another embryo mix-up Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick. It was a big week of news for the ASX healthcare sector with the bourse's fourth largest biotech Cochlear (ASX:COH) downgrading its FY25 net earnings ~4% to $390-400 million, compared with prior guidance in February of $410-430m, on "slower-than-expected sales growth over the last few months". Morgans' healthcare analyst Derek Jellinek wrote in a note to clients consensus for the hearing tech company sat at $411m with Morgans at $412m. While Cochlear continues to expect implant units to grow ~10% in FY25, growth will be weighted to emerging markets as developed market growth has been impacted by slower-than expected market growth and a "small loss" of market share in a few countries. Cochlear now expects services revenue to decline by low double-digits compared to prior expectations for a single-digit decline. "COH believes ongoing work to identify and connect with recipients who could benefit from the latest sound processing technology, combined with the introduction of the new off-the-ear Nucleus Kanso 3 sound processor, which is expected to launch in EU and APAC mid-Jun-25, should lift services revenue in FY26," Jellinek wrote. Following a disappointing H1 FY25 result, Morgans highlighted risks in the services segment (around 25% of sales), driven by slower-than-expected uptake of the Nucleus 8 sound processor, which was launched in FY23, and cost-of-living pressures delaying device replacements. But in some positive news, Cochlear also announced the launch of Nucleus Nexa, the world's first and only smart cochlear implant system, saying it was the "outcome of a 20 year investment in R&D". "A couple of key features include upgraded firmwear, the smallest sound processor and internal memory so that has actually countered the profit downgrade they've announced," Power said. Morgans has a hold rating on Cochlear with a 12-month target price of $285.55. Monash chief quits following another embryo mixup A new acting CEO has been appointed to steer the troubled Monash IVF Group (ASX:MVF), which fell ~27% on Tuesday after reporting another embryo implant bungle. Monash announced on Thursday CEO and managing director Michael Knaap had resigned with CFO and company secretary Malik Jainudeen appointed acting CEO. In the latest incident a patient's own embryo was mistakenly transferred to them, rather than their partner's embryo as specified in the treatment plan at Monash's Clayton laboratory in Melbourne on June 5. Monash said it was conducting an internal investigation to determine the cause of the incident and notified the relevant assisted reproductive technology (ART) regulators, the Victorian health regulator and its insurers. It comes after Monash revealed in April a woman had given birth to a baby that was not hers after receiving the wrong embryo at a Brisbane clinic. An independent review by Fiona McLeod AO SC regarding that incident is currently ongoing and has been extended, with the findings yet to be disclosed. Monash confirmed that its updated profit guidance, issued on May 20, remains unchanged, projecting an underlying NPAT of $27.5 million. Morgans maintains a speculative buy on Monash with a 12-month target price of $1. Israel strikes on Iran add to market uncertainty At 1.45pm on Friday the S&P/ASX 200 Health Care index was down 1.1% for the past five days, while the benchmark ASX 200 was flat for the same period. Markets took a tumble on Friday after reports of Israel strikes against Iran's nuclear sites with the Middle East bracing for retaliation. Power said the escalating conflict adds further complexity to global equity markets still very much being driven by macroeconomic factors and geopolitical tensions. "Markets are still very much broader macro driven including with US President Donald Trump's trade and regulatory policies," Power said. "Investors will now be closely monitoring the escalating tensions in the Middle East." Power's Powerplay: EBR completes raise, starts US rollout EBR Systems (ASX:EBR) is Power's stock of the week after announcing completion of a share purchase plan (SPP) and that the first US commercial patients have been implanted with its WiSE CRT System, the world's only wireless solution for pacing the left side of the heart. The procedures took place at St David's Medical Centre and the Cleveland Clinic, two of several leading US institutions participating in this pilot release of the WiSE CRT System, which was approved by the FDA in April. EBR said the cases represented two of the main indications for WiSE. "Clearly, the first commercial patients implanted with WiSE is a key milestone, as EBR has officially transitioned from a pure R&D focus to a commercial entity," Jellinek wrote in a note to clients. He said importantly, the implants were done in advance of reimbursement and the limited market release of WiSE, which remained on track for October, showcasing the unmet medical need in the initial US$3.6m total addressable market and belief in use of the device. "As this device is a novel treatment option requiring physician education, we view the LMR, targeting key heart failure centres in the US, as an appropriate strategic way to build familiarity and experience, prior to full market release," he wrote. "We see sales surpassing US$80m into CY29. "While certainly not a 'hockey stick', we believe it is a methodical, stage-gated rollout to build strong physician support and closely monitor clinical outcomes, helping to pique interest from any would-be suitor." The company also announced today it had finished its SPP raising $xxm and adding to a fully underwritten Institutional Placement raising $55.9m completed in May. Proceeds from the capital raise will be used to advance its US commercialisation strategy for WiSE. Morgans has a buy rating and 12-month target price of $2.86. Two positive studies for Avita Wounds management company Avita Medical (ASX:AVH) has announced the first clinical publication of its Cohealyx product, which is a collagen-based dermal matrix, in the Journal of Surgery. The publication includes two positive case reports on patients with complex hand wounds treated with Cohealyx. In both instances, the patients sustained full-thickness burns following syncopal episode (temporary loss of consciousness due to a drop in blood flow to the brain). The study showed significant acceleration of wound bed vascularisation and autograft readiness, achieving readiness within five to 10 days compared to the typical two to four weeks. "Clearly, a small sample size and this publication represents the first clinical validation of AVH's preclinical findings but it's a strong start and likely the first of many case-studies to come," Morgans' healthcare analyst Iain Wilkie wrote in a note to clients Avita also announced a new study of its flagship spray-on skin treatment Recell showed it reduced hospital stays by 36% compared to traditional skin grafts. Presented at the British Burn Association's annual meeting, the US-based study analysed outcomes for more than 6,300 patients treated with Recell between 2019 and 2024. All patients had burns covering less than 30% of their total body surface area. The findings showed Recell patients spent on average 6.2 fewer days in hospital, delivering an estimated $300m in healthcare savings over the five-year period. Wilkie wrote that the share price had continued to remain weak following series of missed guidance expectations and dwindling cash reserves. "The point with Avita is they've expanded their product range to treat more of the wound complex and what the market is concerned about is do they need to raise additional funds," Power said. "They've told the market they can see a pathway through to profitability or breakeven by the fourth quarter of this calendar year so as each quarter rolls on we will get more confident that they're able to achieve that." Morgans has a speculative buy rating on Avita and 12-month target price of $3.76. Imricor gets CE Mark for NorthStar Mapping System Imricor Medical Systems (ASX:IMR) has received CE mark (European) certification for its NorthStar Mapping system under the new, more stringent European Union Medical Device Regulations (MDR). NorthStar has been approved as a Class IIa medical device with the certification received ahead of schedule. Imricor is advancing technology for real-time interventional cardiac magnetic resonance (iCMR) ablations, enabling cardiac ablation procedures to be guided by live MRI imaging instead of traditional x-ray fluoroscopy. NorthStar is a key component of its product offering. The certifications follows on from recent European approvals received for its Advantage-MR EP Recorder/Stimulator (Advantage-MR), and its second generation Vision-MR Ablation Catheter. "Imricor will now phase out first generation products approved under the old EU regulations, replacing them with new MDR approved devices," Power said. "We expect sales momentum to steadily build over coming quarters." Power said next catalysts to watch for include additional sales orders in Europe and Middle East and US FDA approval for NorthStar. Imricor is also undertaking its Vision-MR Ablation of Atrial Flutter (VISABL-AFL) pivotal clinical trial to support FDA approval of its products, which it hopes to achieve in 2025. In Europe, where Imricor has already received regulatory approval for atrial flutter, the company has started a pivotal VISABL-VT clinical trial for its second indication, ventricular tachycardia (VT). Morgans has a speculative buy on Monash and 12-month $2.28 target price. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article.

ABC Radio Sydney presenter James Valentine announces omentum cancer diagnosis
ABC Radio Sydney presenter James Valentine announces omentum cancer diagnosis

ABC News

time5 hours ago

  • ABC News

ABC Radio Sydney presenter James Valentine announces omentum cancer diagnosis

I'd really hoped I'd never have to do this again. I've now twice gone on the radio on 702 ABC Sydney, and published articles online, revealing details of my disease. In March 2024, I announced that I had oesophageal cancer, and I was heading off for major surgery and it might be a while before I'd be back. In September 2024, I came back on air, and let everyone know, that I'd had a more minor procedure, removed the tumour in my oesophagus and would then be monitored for any future outbreaks. Well, here in June 2025, I'm telling you the monitoring works very well. My current scans, and a biopsy have confirmed that I have tumours in my omentum. Yes, omentum, I'd never heard of it either. It's described usually as a fatty veil, which extends from the stomach over your intestine. Quite what it does, not sure; partly packaging, partly helping to protect the intestine, possibly some role in dealing with infection. Whatever it's meant to do it is currently largely squeezing my bowel and causing constriction and constipation and general discomfort in that part of the world. Oh, it's been a fun few weeks, my friends. I am now way too familiar with the 'digestive' aisle of my local chemist. So I've been off the last couple of weeks, getting tests, and figuring out what's to be done. As of next week, I will be beginning chemotherapy and immunotherapy. A big blast of 21st century science, that hopefully, will scour it all out and leave me in a position to heal and recover. Immunotherapy is the great hope of everyone these days. I'm eligible, as in it's considered that it's very likely to be effective in my case. I won't be able to keep working so I'll be off air now for at least three months. Side effects of the treatment range from mildly irritating to horrendous, so I think I'll just deal with them. Best I focus on this one thing, and give the medicine and the process its best chance. I've been back playing saxophone and doing some gigs and some live theatre shows as well which, from my point of view on the stage, have been wonderful! So they too will be put on hold for a while until this cancer has abated. Back when this cancer was just a tumour in short pants in my oesophagus I was faced with a choice between the full removal of my oesophagus or the removal of only the tumour, leaving my oesophagus intact. I accepted then that I was making the decision on what I would do. The difficulty with the decision was that both doctors were right; the full surgery was more common and the accepted protocol for my condition, but the lesser procedure was possible. The way I often expressed it then and since, has been to say that I chose a different set of risks. To remove the oesophagus fully was likely to leave me with a long recovery and a potential set of morbidities and difficulties in living that would be challenging. To remove the tumour was to accept that I'd be initially OK, but cancer could return. In fact, in both procedures there was always the likelihood of future cancer. The future's arrived. There may be debate as to whether the full removal might have prevented this, but given that the initial tumour may have been there for a while, undetected and asymptomatic, there's every chance that cancer cells have been out in my body for some time, looking for a place to call home, and the full surgery would not have prevented their spread. I'm not that concerned about that, the how, the why, the might have been. I find cancer, like any other major insult to my being, has a way of bringing me very firmly into the present. What's happening to me, what can I do to fix this, what do I need to do right now this day, this hour, this minute? That's me for the next few months. Treatment, deal with the treatment, rest, build strength for next treatment. In between, be with the people I love. I'm already missing you, I'm already wanting to get back on air. All is not right unless I'm on the radio in the afternoon and there's Rant, and Petty Crimes being solved and couples sharing on This Is What I Live With and all the other glorious, revealing, hilarious and shambolic conversations we share every day. I don't pray, but if you do, please go hard. I can feel your good wishes, love and support and I thank you deeply for it. When I know anything about what's happening, I'll let you know but right now I'm off to the land of the sick. When I get back, you'll hear from me.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store